CYP2C19-related poor drug metabolism is a condition in which the body is unable to properly process certain types of medications such as clopidogrel, mephenytoin, omeprazole, and/or proguanil. As a result, these medications are less effective in affected people who are treated with them. The condition is caused by changes (mutations) in the CYP2C19 gene and is inherited in an autosomal recessive manner. Specific treatment is generally not necessary as affected people do not have additional signs and symptoms aside from poor drug metabolism. However, medications that are poorly metabolized may need to be prescribed in a modified dose or avoided entirely.
Source: GARD Last updated on 05-01-20
MyResults.org is hosted by the Children's Hospital of Philadelphia (CHOP) and entirely funded by the National Human Genome Research Institute (NHGRI) at the National Institutes of Health (NIH). Click on the link to access their information page on CYP2C19-related poor drug metabolism.
Last updated on 04-27-20
Do you have information about a disease, disorder, or syndrome? Want to suggest a symptom?
Please send suggestions to RareGuru!